Sheikh Muhammad Ebtehaj Ali

Sheikh Muhammad Ebtehaj Ali

Auto-generated profile, based on publicly available information

Sheikh Muhammad Ebtehaj Ali

Department of Surgery, Abbasi Shaheed Hospital, Karachi, Pakistan

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2026 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
HRHammad Rao
Hammad Rao
SKSumet Kumar
Sumet Kumar
SASheikh Muhammad Ebtehaj Ali
Sheikh Muhammad Ebtehaj Ali
HAHarmain Muhammad Asif
Harmain Muhammad Asif
MKMukesh Kumar
Mukesh Kumar
ARAdarsh Raja
Adarsh Raja

5 April 2026 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
MKMukesh Kumar
Mukesh Kumar
SKSumet Kumar
Sumet Kumar
SASheikh Muhammad Ebtehaj Ali
Sheikh Muhammad Ebtehaj Ali
HQHadia Qazi
Hadia Qazi
AJArshia Arif Janjua
Arshia Arif Janjua
ACAayush Chaulagain
Aayush Chaulagain
Background: Type 2 diabetes mellitus (T2DM) affects over 500 million people worldwide, with traditional therapies often failing to maintain long‐term glycaemic control. Ecnoglutide, a novel long‐acting GLP‐1 receptor agonist, has emerged as a promising therapeutic option. This systematic review and meta‐analysis evaluated the efficacy and safety of ecnoglutide in adults with T2DM. Methods: Following PRISMA guidelines, we systematically searched PubMed, Cochrane Library, ScienceDirect, ClinicalTrials.gov , and Google Scholar through September 2025. Randomized controlled trials comparing ecnoglutide with placebo or active comparators in adults with T2DM were included. Primary outcomes were changes in HbA1c and body weight. Secondary outcomes included fasting plasma glucose, insulin resistance markers, lipid profile, liver enzymes, and adverse events. Risk of bias was assessed using the Cochrane RoB‐2 tool. Meta‐analysis was performed using random‐effects models, with mean differences and risk ratios calculated at 95% confidence intervals. Results: Four RCTs comprising 1643 participants (1162 receiving ecnoglutide, 444 controls) were included. Ecnoglutide significantly reduced HbA1c (MD = −0.44, 95% CI −0.55 to −0.33, p < 0.00001), body weight (MD = −5.63, 95% CI −7.90 to −3.35, p < 0.01), and fasting plasma glucose (MD = −0.81, 95% CI −1.03 to −0.59, p < 0.00001). Improvements were observed in insulin sensitivity, lipid profile, and liver enzymes. Adverse events occurred more frequently with ecnoglutide (RR = 1.09, p < 0.01), although predominantly gastrointestinal and mild‐to‐moderate, with no significant differences in serious adverse events. Conclusions: Ecnoglutide demonstrates robust efficacy in glycaemic control, weight reduction, and cardiometabolic parameters with an acceptable safety profile in adults with T2DM, supporting its therapeutic potential as a next‐generation GLP‐1 receptor agonist.

21 January 2026 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
ARAdarsh Raja
Adarsh Raja
LKLaksh Kumar
Laksh Kumar
MKMukesh Kumar
Mukesh Kumar
LKLaiba Khurram
Laiba Khurram
SASheikh Muhammad Ebtehaj Ali
Sheikh Muhammad Ebtehaj Ali
ACAayush Chaulagain
Aayush Chaulagain
Background: Acute heart failure (AHF) remains a major cause of morbidity and mortality, especially in hospitalized patients. Inotropic agents like dobutamine have long been used for hemodynamic support, yet concerns over adverse effects such as arrhythmias and increased myocardial oxygen consumption limit their safety. Levosimendan, a calcium sensitizer with vasodilatory properties, offers a potential alternative. This meta-analysis was conducted to evaluate the comparative safety and efficacy of levosimendan versus dobutamine in patients with AHF. Method: A systematic review and meta-analysis was conducted following PRISMA and AMSTAR 2 guidelines. Major databases including PubMed, Cochrane, Embase, and ScienceDirect were searched up to July 2025 without any language restrictions. Sixteen studies including 15 randomized controlled trials and 1 cohort study were evaluated for this study. Outcomes were pooled using a random effects model. Meta-regression was performed to assess the influence of baseline covariates. Result: In the pooled analysis of 16 studies, levosimendan showed a statistically significant reduction in mortality (RR: 0.59; P = 0.0009) compared to dobutamine. While systolic blood pressure and diastolic blood pressure remained comparable, levosimendan led to a marked reduction in pulmonary capillary wedge pressure and improved cardiac index, left ventricular ejection fraction, and mixed venous oxygen saturation. B-type natriuretic peptide and IL-6 levels also declined significantly in the levosimendan group. Adverse events such as hypotension and atrial fibrillation were slightly more frequent with levosimendan, while tachycardia and ischemic events were more common with dobutamine. Overall adverse event rates were similar. Conclusion: Levosimendan demonstrates favorable effects on mortality and key hemodynamic parameters in patients with AHF, especially those on β-blockers or with impaired left ventricular function. Although certain adverse effects like hypotension were more frequent, the overall safety profile remained comparable to dobutamine. These findings suggest levosimendan as a safer and more effective alternative in selected high-risk heart failure populations.

29 July 2026 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
SKSumet Kumar
Sumet Kumar
AJArshia Arif Janjua
Arshia Arif Janjua
LKLaksh Kumar
Laksh Kumar
SASheikh Muhammad Ebtehaj Ali
Sheikh Muhammad Ebtehaj Ali
HAHanzlah Ahmed
Hanzlah Ahmed
ACAayush Chaulagain
Aayush Chaulagain
Background: Uncontrolled hypertension (UH), a severe form of hypertension, persists despite the use of three or more antihypertensive medications. Its growing prevalence, particularly in patients with comorbidities, necessitates novel therapeutic options. Lorundrostat, a selective aldosterone synthase inhibitor, presents a promising mechanism of action by directly reducing aldosterone synthesis while sparing cortisol production, potentially offering an effective and safer alternative to mineralocorticoid receptor antagonists. Objectives: Three randomized controlled trials (RCTs) comprising 1568 participants were included to evaluate the efficacy and safety of lorundrostat in adults with UH as a primary objective, with a decrease in diastolic blood pressure and the incidence of hyperkalemia, hypotension, and serious adverse events, including life-threatening conditions, hospitalization, significant disability, and events resulting in death, as secondary outcomes of the study. Methods: A systematic search of PubMed, Embase, ScienceDirect, Cochrane, and ClinicalTrials.gov up to July 2025 was conducted per PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Included RCTs compared lorundrostat to placebo in adult patients with resistant/UH. Outcomes were pooled using a random-effects model. Meta-regression explored moderators, including age, BMI, and comorbidities. Results: Three RCTs ( n = 1568) met inclusion criteria. Lorundrostat significantly reduced systolic blood pressure [mean difference (MD) = –8.40 mmHg, 95% confidence interval (CI) (–9.81, –6.99), P < 0.00001, I 2 = 0%] and diastolic blood pressure [MD = –3.84 mmHg, 95% CI (–5.06, –2.63), P < 0.00001, I 2 = 0%]. Adverse events were more frequent in the lorundrostat group [risk ratio (RR) = 1.41], with notable risks of hypotension (RR = 3.10) and hyperkalemia (RR = 7.31), though serious adverse events were not significantly increased (RR = 1.28). Conclusion: Lorundrostat demonstrates significant antihypertensive efficacy and a manageable safety profile in UH patients. Larger, long-term trials are warranted to further validate its safety across broader populations and complete its efficacy profile, emphasizing the unknown long-term cardiovascular outcomes of the intervention.

13 October 2026 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
PDF file
MFMuhammad Farhan
Muhammad Farhan
MMMuhammad Murtaza
Muhammad Murtaza
MRMuhammad Mujtaba Rasool
Muhammad Mujtaba Rasool
FKFarah Khan
Farah Khan
HAHammad Amjad
Hammad Amjad
FHFurqan Hassan
Furqan Hassan
Background: Atherosclerotic cardiovascular disease remains a leading cause of global mortality, with low‐density lipoprotein cholesterol (LDL‐C) reduction being the cornerstone of prevention. Despite effective therapies, many high‐risk patients do not achieve recommended LDL‐C targets. Enlicitide (MK‐0616), an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, offers a potential alternative to injectable PCSK9‐directed therapies. Objective: To evaluate the efficacy and safety of enlicitide in adults with hypercholesterolemia and assess its dose‐dependent effects on lipid parameters. Methods: We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) according to PRISMA 2020 guidelines. PubMed, Embase, Scopus, ClinicalTrials.gov, and Google Scholar were searched from inception through March 2026. Random‐effects meta‐analysis using restricted maximum likelihood estimation was performed. The primary outcome was the percentage change in LDL‐C from baseline. Secondary outcomes included non‐high‐density lipoprotein cholesterol (non‐HDL‐C), apolipoprotein B (ApoB), lipoprotein(a), triglycerides, and safety outcomes. Risk of bias and certainty of evidence were assessed using RoB 2.0 and GRADE. Results: Three placebo‐controlled RCTs involving 3593 participants were included. Enlicitide significantly reduced LDL‐C compared with placebo (mean difference [MD], −56.19%; 95% CI, −64.14 to −48.25; p < 0.0001), with moderate heterogeneity ( I 2 = 56.9%). Significant reductions were also observed in non‐HDL‐C (MD, −51.36%), ApoB (MD, −47.09%), lipoprotein(a) (MD, −20.10%), and triglycerides (MD, −13.12%). A numerical dose–response gradient was observed, although subgroup differences were not statistically significant. Sensitivity analyses supported the robustness of the findings. Rates of adverse events, serious adverse events, and treatment discontinuation were comparable between groups. Conclusion: Enlicitide produced substantial reductions in LDL‐C and other atherogenic lipid parameters without an apparent increase in adverse events. However, findings should be interpreted cautiously given the limited number of trials, moderate heterogeneity, and reliance on surrogate endpoints. Dose–response, duration‐related lipoprotein(a), and triglyceride findings were exploratory and substantially driven by single trials. Long‐term cardiovascular outcomes trials are needed to establish clinical benefit.